Milvexian
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Milvexian
- Molecular weight
- 626.46
- Structure (SMILES)
- C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O
- bms 986177
- BMS 986177
- Bms-986177
- BMS-986177
- BMS-986177 Oral Solution
- jnj 70033093
- Jnj-70033093
- JNJ-70033093
- JNJ-70033093 100 mg
- JNJ-70033093 200 mg
- JNJ-70033093 25 mg
- JNJ-70033093 50 mg
- milvexian
- Milvexian
- MILVEXIAN
- milvexian [INN]
- MILVEXIAN [USAN]
- Milvexian [WHO-DD]
- milvexian inn
- milvexian usan
- milvexian who dd
- CAS registry numbers
- 1802425-99-5
- ChEMBL ID
- CHEMBL4112929
- InChIKey
- FSWFYCYPTDLKON-CMJOXMDJSA-N
- PubChem compound IDs
- 118277544
- FDA ingredient codes (UNII)
- 0W79NDQ608
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- milvexian
- Type
- Synthetic organic
- Drug name stem
- -xian
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- coagulation factor XI
- Gene symbol
- F11
- Protein identifier
- P03951
- Median affinity
- 9.96
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- kallikrein B1
- Gene symbol
- KLKB1
- Protein identifier
- P03952
- Median affinity
- 7.36
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- chymotrypsin C
- Gene symbol
- CTRC
- Protein identifier
- Q99895
- Median affinity
- 7.46
- Affinity units
- pKi
- Mechanism
- Coagulation factor XI inhibitor
- Action type
- Inhibitor
- Target
- Coagulation factor XI
- Protein identifier
- P03951
Open Targets mechanisms
- Mechanism
- Coagulation factor XI inhibitor
- Action type
- Inhibitor
- Target
- Coagulation factor XI
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Acute Coronary Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005672
- Subject identifier
- D054058
- Condition
- Thrombosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0000831
- Subject identifier
- D013927
- Condition identifier
- EFO_0000275
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005672
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009909
- Highest recorded phase
- 1
- Condition identifier
- HP_0002140
- Highest recorded phase
- 2
- Condition identifier
- HP_0002637
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000831
- Highest recorded phase
- 1
- Condition identifier
- MONDO_1060198
- Highest recorded phase
- 2
- NCT02608970
- NCT02807909
- NCT02959060
- NCT02982707
- NCT03196206
- NCT03224260
- NCT03362437
- NCT03939702
- NCT05754957
- NCT05757869
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 1
- Polar surface area
- 125.41
- Calculated partition coefficient (ALogP)
- 5.8
- Calculated partition coefficient (XLogP)
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 4
- Heavy atoms
- 43
- Molecular formula
- C28H23Cl2F2N9O2
- Monoisotopic mass
- 625.1319827
- Natural product
- No
- Recorded assays
- 57
- Active assays
- 21
Active assay types
- Confirmatory
Solubility
- Median
- 7
- Mean
- 7
- Minimum
- 6
- Maximum
- 8
- Unit
- ug/mL
- Assays
- 2
- Standard deviation
- 1.41421
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 25
- Mean
- 25
- Minimum
- 18
- Maximum
- 32
- Unit
- %
- Assays
- 4
- Standard deviation
- 8.0829
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (26)
- A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants
- A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants
- A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants
- A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
- A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
- A Study of JNJ-70033093 and Digoxin in Healthy Participants
- A Study of JNJ-70033093 in Healthy Participants
- A Study of Milvexian in Healthy Adult Females
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
- A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects
- A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
- A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis
- A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects
- A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects
- A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
- An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants
In development for (3)
- Acute coronary syndrome Phase 3
- Atrial fibrillation Phase 3
- Thrombotic disease Phase 1
Targets (1)
- F11 Coagulation factor XI inhibitor